Amsterdam Molecular Therapeutics’ (AMT) lead product ,Glybera, has demonstrated long-term health benefits in one-time administration. The data from two clinical trials showed that one administration with Glybera brings
Allergan has received FDA approval for OZURDEX (dexamethasone intravitreal implant) 0.7mg, as the first drug therapy for the treatment of macular edema, following branch retinal vein occlusion (BRVO)
Novartis has received FDA approval for Ilaris (canakinumab), for the treatment of cryopyrin-associated periodic syndrome (CAPS) in children and adults. The FDA granted priority review to Ilaris, based
Manhattan Pharmaceuticals (Manhattan) has provided update on ongoing development program for Hedrin. Hedrin is a next generation, non-pesticide treatment for Pediculosis (head lice). The drug is currently being
Highlights: Group operating profit before non-recurring costs GBP334,000 (2008: GBP1,033,000) Non-recurring costs of GBP1,117,000 primarily represent business relocation expenses and redundancy and employment contract severance costs Loss before
New Jersey, US- based Strativa ,the proprietary products division of a wholly owned subsidiary of Par declared that its development partner, BioAlliance has submitted a New Drug Application
Mylan Pharmaceuticals, a subsidiary of Mylan has received approval from the FDA for supplemental Abbreviated New Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This strength is
CuraGen’s phase I/II trial, evaluating CR011-vcMMAE for the treatment of advanced breast cancer, has met the efficacy criteria for advancement to the second stage of enrollment. CR011-vcMMAE is
NxStage’ subsidiary, Medisystems has signed a five year distribution agreement with Gambro. Under the agreement, Medisystems will supply blood tubing sets, including the ReadySet and the Streamline to
The US Federal Trade Commission has granted Johnson & Johnson, the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, with respect to its previously
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.